Immunization, Vaccines and Biologicals

Countries

Share

At a glance, country pages present a summary of the immunization financing situation for available countries and provide key data and indicators of interest. These pages are intended for country-focused analysis and other relevant country specific information. The key information, data and indicators provided in these pages are based on either the GAVI Financial Sustainability Plans or national multi-year plan for immunization (cMYP). Individual pages offer the possibility to download the complete Financial Sustainability Plan documents, accompanying annex materials, and or the national multi-year plan for immunization (cMYP) and costing.

Status of National Comprehensive Multi-Year Plans (cMYPs)

To view the country pages, use the search and filtering options below the map.

Figure 1: Available country pages by document type

FSP: GAVI immunization Financial Sustainability Plan
cMYP: WHO-UNICEF comprehensive Multi-Year Plan for immunization
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
Copyright WHO 2011. All rights reserved

Autonomous or semi-autonomous territory:


Disclaimer

The data on the immunization financing website is derived from the information obtained from available Financial Sustainability Plans (FSP) and multi-year immunization plans (cMYPs) developed by countries and submitted to GAVI as part of an application for support. Adjustments to the data were made to improve cross country comparisons and fixing known errors in the data. The World Health Organization and GAVI Alliance do not represent or endorse the accuracy or reliability of this data, and shall not be liable for damages incurred as a result of its use.


Last updated: November 2013